Insider Filing: Versant Disposes 260,713 LENZ Shares in Mid‑August 2025
Rhea-AI Filing Summary
Versant-affiliated investment vehicles reported multiple sales of LENZ Therapeutics common stock in mid-August 2025. Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P. and Versant Vantage II, L.P. sold a total of 260,713 shares across transactions dated 08/15/2025 and 08/18/2025 at prices ranging from $38.26 to $39.50 (a weighted average price reported for some sales as $38.5611). After the reported disposals, the filing shows Versant Venture Capital VI beneficially owned 1,430,848 shares (direct) and 977,963 shares (indirect) in related accounts; Versant Vantage II and affiliated entities reported 842,162 shares (indirect). The filing includes customary disclosure of the general partner/GP-GP structure and disclaimers of beneficial ownership except for pecuniary interests.
Positive
- None.
Negative
- Reported sales of 260,713 shares on 08/15/2025 and 08/18/2025 at prices between $38.26 and $39.50, increasing publicly available float over those dates
- Insider-affiliated entities reduced positions via direct disposals (e.g., 145,051 and 69,949-share sales noted), which may be viewed by some investors as a negative signal
- Complex ownership chain across GP and GP-GP entities requires careful reading to understand which entities retain direct versus indirect beneficial ownership
Insights
TL;DR: Versant entities executed structured share sales totaling 260,713 LENZ shares at ~$38.26–$39.50; holdings remain substantial.
The Form 4 documents multiple sales by affiliated venture funds on 08/15/2025 and 08/18/2025 totaling 260,713 shares at prices within the disclosed range. Despite these disposals, the reporting entities continue to hold large positions (over 1.4M direct shares reported for one vehicle and additional indirect holdings). This is a straightforward insider transaction disclosure showing liquidity events by institutional holders rather than option exercises or derivative activity; no derivative securities were reported as acquired or disposed in Table II. Impact is informational for share supply and insider activity.
TL;DR: Routine partner-level sales by affiliated funds with standard GP/GP-GP disclosure; governance structure clearly described.
The filing includes detailed ownership chain disclosures: GP and GP-GP entities may be deemed to share voting and dispositive power but disclaim beneficial ownership except for pecuniary interests. Signatures from Max Eisenberg as Chief Operating Officer appear on behalf of multiple related entities, and standard footnotes explain the relationships. The disclosure meets Section 16 requirements for reporting changes in beneficial ownership by insiders and affiliated funds.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 30,628 | $38.5611 | $1.18M |
| Sale | Common Stock | 15,085 | $38.5611 | $582K |
| Sale | Common Stock | 145,051 | $39.50 | $5.73M |
| Sale | Common Stock | 69,949 | $39.50 | $2.76M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.26 to $39.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
